<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003079</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065773</org_study_id>
    <secondary_id>P30CA016059</secondary_id>
    <secondary_id>MCV-MCC-9612-2E</secondary_id>
    <secondary_id>NCI-T97-0011</secondary_id>
    <nct_id>NCT00003079</nct_id>
  </id_info>
  <brief_title>Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma</brief_title>
  <official_title>Phase I Study of Bryostatin 1 (NSC 339555) and High-Dose 1-Beta-D-Arabinofuranosylcytosine (HiDAC) in Patients With Refractory Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 and high dose cytarabine in&#xD;
      treating patients with refractory or relapsed acute myelocytic or acute lymphocytic leukemia,&#xD;
      chronic myelogenous leukemia or refractory or relapsed lymphoblastic lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Define the maximum tolerated dose (MTD) of bryostatin 1 administered before&#xD;
      and after high dose cytarabine in patients with refractory or relapsed acute myelocytic&#xD;
      leukemia or acute lymphocytic leukemia, chronic myelogenous leukemia, or refractory or&#xD;
      relapsed lymphoblastic lymphoma. II. Describe the toxic effects of bryostatin 1 and high dose&#xD;
      cytarabine in these patients. III. Describe the time course of bryostatin 1 induced&#xD;
      modulation of leukemic blast total protein kinase C (PKC) activity. IV. Describe bryostatin 1&#xD;
      pharmacokinetics. V. Correlate bryostatin 1 induced modulation of leukemic cell PKC activity&#xD;
      or leukemic cell maturation with high dose cytarabine mediated apoptosis.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study. Patients receive bryostatin 1 by continuous&#xD;
      infusion over 24 hours on day 1. One hour after completion of bryostatin 1, patients receive&#xD;
      high dose cytarabine IV over 3 hours every 12 hours on days 2-4. Patients again receive&#xD;
      cytarabine over 3 hours every 12 hours on days 9-11, followed 1 hour later by bryostatin 1 by&#xD;
      continuous infusion over 24 hours beginning on day 11. Patients achieving complete remission&#xD;
      may receive up to 4 courses of consolidation chemotherapy. Consolidation chemotherapy is the&#xD;
      same as induction chemotherapy except patients receive only 2 doses of cytarabine after day 1&#xD;
      completion of bryostatin and only 2 doses of cytarabine prior to the day 11 dose of&#xD;
      bryostatin. Patients achieving partial remission may receive a second course of induction&#xD;
      chemotherapy. In the absence of dose limiting toxicity in the first 3 patients treated,&#xD;
      subsequent cohorts of 6 patients receive escalating doses of bryostatin 1 on the same&#xD;
      schedule. If dose limiting toxicity occurs in 2 of 6 patients at a given dose level, then&#xD;
      dose escalation ceases and the current dose is defined as the maximum tolerated dose.&#xD;
      Patients are followed every 6 months until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1997</start_date>
  <completion_date type="Actual">May 2001</completion_date>
  <primary_completion_date type="Actual">May 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">30</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bryostatin 1</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed primary refractory or relapsed acute&#xD;
        myelocytic leukemia (AML) or acute lymphocytic leukemia (ALL), chronic myelogenous leukemia&#xD;
        (CML) in blast crisis, or refractory or relapsed lymphoblastic lymphoma Priority is given&#xD;
        to patients previously treated with conventional high dose cytarabine regimen without&#xD;
        bryostatin 1 Eligible if previously failed a conventional high dose cytarabine regimen or&#xD;
        if underwent subsequent high dose therapy with bone marrow/stem cell transplantation with&#xD;
        curative intent&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over (must be 60 or under if receiving higher dose of&#xD;
        cytarabine) Performance status: Karnofsky 60-100% Life expectancy: Not specified&#xD;
        Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL (bilirubin no&#xD;
        greater than 3.0 mg/dL and conjugated bilirubin no greater than 0.5 mg/dL if Gilbert's&#xD;
        disease and predominantly unconjugated hyperbilirubinemia present) AST no greater than 2.5&#xD;
        times upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN Renal:&#xD;
        Creatinine clearance at least 40 mL/min (at least 60 mL/min if receiving higher dose of&#xD;
        cytarabine) Pulmonary: No clinically significant pulmonary disease Other: Not pregnant No&#xD;
        patients who are poor medical risks because of nonmalignant systemic disease No serious,&#xD;
        active, uncontrolled infection No prior or concurrent medical status that would make&#xD;
        assessing cortical or cerebellar neurologic toxicity difficult&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Recovery from the major toxic effects of prior therapy required&#xD;
        Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics At&#xD;
        least 24 hours since prior chemotherapy with hydroxyurea At least 3 weeks since other prior&#xD;
        systemic chemotherapy No prior clinically significant cerebellar toxicity due to cytarabine&#xD;
        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Grant, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Cornell Campus</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>May 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2004</study_first_posted>
  <last_update_submitted>February 15, 2010</last_update_submitted>
  <last_update_submitted_qc>February 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>National Cancer Institute</name_title>
  </responsible_party>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Bryostatin 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

